Mar. 30, 2015
March 30, 2015. CASI Pharmaceuticals has announced the China Food and Drug Administration’s (CFDA) approval to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.
The approval will allow CASI to expand its ongoing Phase 2 OCCC trial currently underway in multiple centers in North America. This is the company’s third approval of a global Phase 2 clinical trial in China.